More tools:Markets·Screener·Research·Chat

Cardiff Oncology, Inc. Common Stock (CRDF) Financial Statements

Cardiff Oncology, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SLWWP7
XNAS · usd
1.10▲ 0.01 (0.92%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.09
Day's Range1.05 – 1.13
52-Week Range0.76 – 3.31
Volume703.0K
Avg Volume743.1K
Share Statistics
Shares Outstanding
Employees31
ExchangeXNAS
Listed1997-05-22
Share count as of August 6, 2026
Loading Income Statement…
Key questions about Cardiff Oncology, Inc. Common Stock (CRDF)
What is Cardiff Oncology, Inc. Common Stock's Market Cap?
Cardiff Oncology, Inc. Common Stock's Market Cap is $85.6M, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's Enterprise Value?
Cardiff Oncology, Inc. Common Stock's Enterprise Value is $399.4M, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's Trailing P/E?
Cardiff Oncology, Inc. Common Stock's Trailing P/E is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's Price / Sales?
Cardiff Oncology, Inc. Common Stock's Price / Sales is 0.0×, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's EV / Revenue?
Cardiff Oncology, Inc. Common Stock's EV / Revenue is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's EV / EBITDA?
Cardiff Oncology, Inc. Common Stock's EV / EBITDA is 0.8×, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's Revenue (TTM)?
Cardiff Oncology, Inc. Common Stock's Revenue (TTM) is $1.8B, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's Net Income (TTM)?
Cardiff Oncology, Inc. Common Stock's Net Income (TTM) is $409.1M, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's EBITDA?
Cardiff Oncology, Inc. Common Stock's EBITDA is $520.9M, based on as-reported figures from SEC (XBRL) filings.
What is Cardiff Oncology, Inc. Common Stock's Diluted EPS (TTM)?
Cardiff Oncology, Inc. Common Stock's Diluted EPS (TTM) is 5.26, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Royalty revenues
YoY growth-14.0%-62.4%+10.3%-27.3%
Costs and expenses:
Research and development—
Selling, general and administrative—
Total operating expenses
% of revenue9345.2%31441.5%69.2%10078.3%
Loss from operations
% of revenue-9245.2%-31341.5%30.8%-9978.3%
Other income (expense), net:
Interest income—
Other income (expense), net
Total other income (expense), net
Net loss
% of revenue-8876.9%-30109.8%24.5%-9381.7%
Preferred stock dividend payable on Series A Convertible Preferred Stock—
Net loss attributable to common stockholders—
Net loss per common share - basic—
Net loss per common share - diluted—